X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs AUROBINDO PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS AUROBINDO PHARMA NOVARTIS/
AUROBINDO PHARMA
 
P/E (TTM) x 387.3 17.0 2,275.6% View Chart
P/BV x 31.0 3.4 923.0% View Chart
Dividend Yield % 1.5 0.4 395.5%  

Financials

 NOVARTIS   AUROBINDO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
AUROBINDO PHARMA
Mar-18
NOVARTIS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs758809 93.7%   
Low Rs579504 114.9%   
Sales per share (Unadj.) Rs228.4281.1 81.3%  
Earnings per share (Unadj.) Rs31.741.4 76.7%  
Cash flow per share (Unadj.) Rs32.850.9 64.4%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.50.4 392.8%  
Book value per share (Unadj.) Rs297.1199.4 149.0%  
Shares outstanding (eoy) m24.69585.88 4.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.92.3 125.3%   
Avg P/E ratio x21.115.9 132.7%  
P/CF ratio (eoy) x20.412.9 158.1%  
Price / Book Value ratio x2.23.3 68.3%  
Dividend payout %31.56.0 521.2%   
Avg Mkt Cap Rs m16,505384,630 4.3%   
No. of employees `0000.717.3 3.9%   
Total wages/salary Rs m1,44521,308 6.8%   
Avg. sales/employee Rs Th8,441.39,500.7 88.8%   
Avg. wages/employee Rs Th2,163.61,229.4 176.0%   
Avg. net profit/employee Rs Th1,173.11,397.9 83.9%   
INCOME DATA
Net Sales Rs m5,639164,666 3.4%  
Other income Rs m1,7181,020 168.5%   
Total revenues Rs m7,357165,686 4.4%   
Gross profit Rs m-6337,718 -0.2%  
Depreciation Rs m255,580 0.5%   
Interest Rs m55777 7.1%   
Profit before tax Rs m1,57532,380 4.9%   
Minority Interest Rs m031 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7928,183 9.7%   
Profit after tax Rs m78424,229 3.2%  
Gross profit margin %-1.122.9 -4.8%  
Effective tax rate %50.325.3 198.9%   
Net profit margin %13.914.7 94.4%  
BALANCE SHEET DATA
Current assets Rs m9,522121,878 7.8%   
Current liabilities Rs m3,29686,806 3.8%   
Net working cap to sales %110.421.3 518.4%  
Current ratio x2.91.4 205.8%  
Inventory Days Days37130 28.2%  
Debtors Days Days2868 41.6%  
Net fixed assets Rs m4681,037 0.1%   
Share capital Rs m123586 21.1%   
"Free" reserves Rs m7,213116,218 6.2%   
Net worth Rs m7,336116,804 6.3%   
Long term debt Rs m04,512 0.0%   
Total assets Rs m11,105211,052 5.3%  
Interest coverage x29.542.7 69.1%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.8 65.1%   
Return on assets %7.611.8 63.8%  
Return on equity %10.720.7 51.5%  
Return on capital %22.227.4 81.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6180,727 0.1%   
Fx outflow Rs m3,63034,700 10.5%   
Net fx Rs m-3,57046,027 -7.8%   
CASH FLOW
From Operations Rs m1,61019,548 8.2%  
From Investments Rs m687-19,570 -3.5%  
From Financial Activity Rs m-2,6778,642 -31.0%  
Net Cashflow Rs m-3808,922 -4.3%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.0 25.2%  
FIIs % 1.6 27.7 5.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.2 210.8%  
Shareholders   41,647 69,601 59.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALKEM LABORATORIES  PLETHICO PHARMA  WOCKHARDT  TORRENT PHARMA  FRESENIUS KABI ONCO.  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

US China Trade War Escalations and Election Results: Volatility Set to Rule(Podcast)

India could be the latest direct victim of the US-China trade war. The increasing escalations have already slowed down global growth.

Related Views on News

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 19.3% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (up 19.3% YoY). Sales on the other hand came in at Rs 53 bn (up 21.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of AUROBINDO PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 21.6% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (down 21.6% YoY). Sales on the other hand came in at Rs 48 bn (up 7.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

Limited Upside, Higher Downside(The Honest Truth)

May 6, 2019

The market's irrational reaction may present opportunities for a limited period of time.

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


May 17, 2019 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STERLING BIOTECH COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS